Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.

@article{Amantea1997PopulationPA,
  title={Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.},
  author={Michael A. Amantea and Alan Forrest and Donald W. Northfelt and Richard D. Mamelok},
  journal={Clinical pharmacology and therapeutics},
  year={1997},
  volume={61 3},
  pages={301-11}
}
OBJECTIVE To characterize the population pharmacokinetics of pegylated-liposomal doxorubicin in patients with acquired immunodeficiency disease (AIDS)-related Kaposi's sarcoma and to explore the relationship between response of the cutaneous Kaposi's sarcoma lesions to treatment and measures of drug exposure. METHODS Forty-three male patients (median age… CONTINUE READING